Clinical Practice Guidelines Antenatal care - Module I

9.7 References

Page last updated: 02 April 2013

Abeywardana S & Sullivan EA (2008) Congenital Anomalies in Australia 2002–2003. AIHW Cat. no. PER 41. Sydney: Australian Institute of Health and Welfare National Perinatal Statistics Unit.

ACOG (2007) ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. American College of Obstetricians and Gynecologists. Obstet Gynecol 109(1): 217–27.

Alexioy E, Alexioy E, Trakakis E, et al (2009) Predictive value of increased nuchal translucency as a screening test for the detection of fetal chromosomal abnormalities. J Matern Fetal Neonatal Med 22(10): 857–62.

Alfirevic Z, Sundberg K, Brigham S (2003) Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database of Systematic Reviews DOI: 10.1002/14651858.CD003252.

Arimori N (2006) Randomized controlled trial of decision aids for women considering prenatal testing: The effect of the Ottawa Personal Decision Guide on decisional conflict. Japan J Nursing Sci 3(2): 119–30.

Caughey AB, Musci TJ, Belluomini J et al (2007) Nuchal translucency screening: how do women actually utilize the results? Prenat Diagn 27(2): 119–23.

Centini G, Rosignoli L, Scarinci R et al (2005) Re-evaluation of risk for Down syndrome by means of the combined test in pregnant women of 35 years or more. Prenat Diagn 25(2): 133–36.

Chasen ST, McCullough LB, Chervenak FA et al (2004) Is nuchal translucency screening associated with different rates of invasive testing in an older obstetric population? Am J Obstet Gynecol 190(3): 769–74.

Chou CY, Hsieh FJ, Cheong ML et al (2009) First-trimester Down syndrome screening in women younger than 35 years old and cost-effectiveness analysis in Taiwan population. J Eval Clin Pract 15(5): 789–96.

Coory MD, Roselli T, Carroll HJ (2007) Antenatal care implications of population-based trends in Down syndrome birth rates by rurality and antenatal care provider, Queensland, 1990–2004. Med J Aust 186(5): 230–34.

Dormandy E, Michie S, Hooper R et al (2005) Low uptake of prenatal screening for Down syndrome in minority ethnic groups and socially deprived groups: A reflection of women’s attitudes or a failure to facilitate informed choices? Int J Epidemiol 34 (2): 346–52.

Edwards A, Mulvey S, Wallace EM (2003) The effect of image size on nuchal translucency measurement. Prenat Diagn 23: 284–86.

Gebb J & Dar P (2009) Should the first-trimester aneuploidy screen be maternal age adjusted? Screening by absolute risk versus risk adjusted to maternal age. Prenat Diagn 29 (3): 245–47.

Grati FR, Barlocco A, Grimi B et al (2010) Chromosome abnormalities investigated by non-invasive prenatal testing account for approximately 50% of fetal unbalances associated with relevant clinical phenotypes. Am J Med Gen 152A(6): 1434–42.
Top of page
Green JM, Hewison J, Bekker H et al (2004) Psychosocial aspects of genetic screening of pregnant women and newborns: A systematic review. Health Technol Assess 8(33): iii, ix–x, 1–109.

Hagen A, Entezami M, Gasiorek-Wiens A et al (2010) The impact of first trimester screening and early fetal anomaly scan on invasive testing rates in women with advanced maternal age. Ultraschall Med [Epub ahead of print].

HGSA & RANZCOG (2007) Prenatal Screening Tests for Trisomy 21 (Down Syndrome), Trisomy 18 (Edwards Syndrome) and Neural Tube Defects. College Statement C-Obs 4. Human Genetic Society of Australasia and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists.

Hunt J (2004) Pregnancy Care and Problems for Women giving Birth at Royal Darwin Hospital. Victoria: Centre for the Study of Mothers’ and Children’s Health.

Leonard S, Bower C, Petterson B et al (2000) Survival of infants with Down’s syndrome 1980–96. Paed Perinat Epidemiol 14: 163–71.

Lo TK, Lai FK, Leung WC et al (2010) A new policy for prenatal screening and diagnosis of Down syndrome for pregnant women with advanced maternal age in a public hospital. J Matern Fetal Neonatal Med 23(8): 914–19.

Marsk A, Grunewald C, Saltvedt S et al (2006) If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases. Acta Obstet Gynecol Scand 85(5): 534–38.

MSHR (2010) Screening for Fetal Anomalies: Views of Indigenous People and their Health Care Providers. Darwin: Menzies School of Health Research.

Muggli EE, McCloskey D, Halliday JL (2006) Health behaviour modelling for prenatal diagnosis in Australia: a geodemographic framework for health service utilisation and policy development. BMC Health Serv Res 6(1): 109.

Nadel AS & Likhite ML (2009) Impact of first-trimester aneuploidy screening in a high-risk population. Fetal Diagn Ther 26(1): 29–34.

Nagle C, Lewis S, Meiser B et al (2006) Evaluation of a decision aid for prenatal testing of fetal abnormalities: a cluster randomised trial. BMC Public Health 13(6): 96.

Nagle C, Gunn J, Bell R et al (2008) Use of a decision aid for prenatal testing of fetal abnormalities to improve women’s informed decision making: a cluster randomised controlled trial. Brit J Obstet Gynaecol 115(3): 339–47.

NICE (2008) Antenatal Care. Routine Care for the Healthy Pregnant Woman. National Collaborating Centre for Women’s and Children’s Health. Commissioned by the National Institute for Health and Clinical Excellence. London: RCOG Press.

Nicolaides KH (2004) Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 191: 45–67.

Nicolaides KH, Spencer K, Avgidou K et al (2005) Multicenter study of first-trimester screening for trisomy 21 in 75,821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage firsttrimester screening. Ultrasound Obstet Gynecol 25(3): 221–26.

Nisbet DL, Robertson AC, Schluter PJ et al (2010) Auditing ultrasound assessment of fetal nuchal translucency thickness: A review of Australian national data 2002–2008. Aust NZ J Obstet Gynaecol 50: 450–55.

NSW Health (2007) Prenatal Testing/Screening for Down Syndrome & Other Chromosomal Abnormalities. PD2007_067. Sydney: NSW Health.

O’Leary P, Breheny N, Reid G et al (2006) Regional variations in prenatal screening across Australia: stepping towards a national policy framework. Aust NZ J Obstet Gynaecol 46: 427–32.

Pandya PP, Snijders RJM, Johnson SJ et al (1995) Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Brit J Obstet Gynaecol 102: 957–62.

Philip J, Silver RK, Wilson RD et al (2004) Late first-trimester invasive prenatal diagnosis: results of an international randomized trial. Obstet Gynecol 103(6): 1164–73.

Philipson EH, Callahan M, Jelovsek JE (2008) First-trimester and second-trimester screening at a community hospital: Experience from the first year of implementation. Obstet Gynecol 112(2 Pt 1): 218–22.

Saltvedt S, Almström H, Kublickas M et al (2005) Screening for Down syndrome based on maternal age or fetal nuchal translucency: a randomized controlled trial in 39572 pregnancies. Ultrasound Obstet Gynecol 25(6): 537–45.

Schmidt P, Hörmansdörfer C, Golatta M et al (2010) Analysis of the distribution shift of detected aneuploidies by age independent first trimester screening. Arch Gynecol Obstet 281(3): 393–99.
Top of page
Scott F, Peters H, Bonifacio M et al (2004) Prospective evaluation of a first trimester screening program for Down syndrome and other chromosomal abnormalities using maternal age, nuchal translucency and biochemistry in an Australian population. Aust NZ J Obstet Gynaecol 44
(3): 205–09.

Soergel P, Pruggmayer M, Schwerdtfeger R et al (2006) Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: A regional experience from Germany. Fetal Diagn Ther 21(3): 264–68.

Souka AP, Krampl E, Bakalis S et al (2001) Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet Gynecol 18: 9–17.

Souka AP, Snidjers RJM, Novakov A et al (1998) Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10–14 weeks of gestation. Ultrasound Obstet Gynecol 11: 391–400.

Stenhouse EJ, Crossley JA, Aitken DA et al (2004) First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice. Prenatal Diagnosis 24(10): 774–80.

Wapner R, Thom E, Simpson JL et al (2003) First-trimester screening for trisomies 21 and 18. New Engl J Med 349 (15): 1405–13.

Zournatzi V, Daniilidis A, Karidas C et al (2008) A prospective two years study of first trimester screening for Down Syndrome. Hippokratia 12(1): 28–32.